AEON Biopharma Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • AEON

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.15
  • (As of Friday Closing)

AEON Biopharma General Information

Description

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.

Contact Information

Formerly Known As
Alphaeon
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 130 Vantis Drive
  • Suite 170
  • Aliso Viejo, CA 92656
  • United States
+1 (949)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
ASE
Corporate Office
  • 130 Vantis Drive
  • Suite 170
  • Aliso Viejo, CA 92656
  • United States
+1 (949)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AEON Biopharma Stock Performance

As of 13-Nov-2026, AEON Biopharma’s stock price is $0.15. Its current market cap is $10.9M with 71.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.15 $0.16 $0.13 - $1.45 $10.9M 71.5M 7.59M -$4.39

AEON Biopharma Financials Summary

As of 30-Jun-2026, AEON Biopharma has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2022 31-Dec-2022
EV 15,305 25,644 37,549
Revenue 0 0 0 0
EBITDA (54,545) (39,144) 42,102 (52,488)
Net Income (54,623) (39,222) 42,005 (52,556)
Total Assets 5,910 5,560 3,142 10,778
Total Debt 2,775 35,745 12,955 131,791
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AEON Biopharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AEON Biopharma‘s full profile, request access.

Request a free trial

AEON Biopharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimil
Drug Discovery
Aliso Viejo, CA
8 As of 2025

Paris, France
 

Washington, DC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AEON Biopharma Competitors (7)

One of AEON Biopharma’s 7 competitors is Ipsen, a Formerly PE-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ipsen Formerly PE-Backed Paris, France
Vanda Pharmaceuticals Formerly VC-backed Washington, DC
Contineum Therapeutics Formerly VC-backed San Diego, CA
Tris Pharma Private Debt Financed Monmouth Junction, NJ
Nektar Therapeutics Formerly VC-backed San Francisco, CA
You’re viewing 5 of 7 competitors. Get the full list »

AEON Biopharma Patents

AEON Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023384143-A1 Optimization of botulinum toxin treatment of migraine and other headache disorders Pending 22-Nov-2022
WO-2024112924-A2 Optimization of botulinum toxin treatment of migraine and other headache disorders Inactive 22-Nov-2022
WO-2024112924-A3 Optimization of botulinum toxin treatment of migraine and other headache disorders Inactive 22-Nov-2022
AU-2023375349-A1 Compositions for use in treating headache disorders Pending 07-Nov-2022
US-20260355285-A1 Compositions for use in treating headache disorders Pending 07-Nov-2022 A61K38/26
To view AEON Biopharma’s complete patent history, request access »

AEON Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AEON Biopharma Acquisitions (1)

AEON Biopharma’s most recent deal was a Merger/Acquisition with Priveterra Acquisition for . The deal was made on 21-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Priveterra Acquisition 21-Jul-2023 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view AEON Biopharma’s complete acquisitions history, request access »

AEON Biopharma ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view AEON Biopharma’s complete esg history, request access »

AEON Biopharma FAQs

  • When was AEON Biopharma founded?

    AEON Biopharma was founded in 2012.

  • Where is AEON Biopharma headquartered?

    AEON Biopharma is headquartered in Aliso Viejo, CA.

  • What is the size of AEON Biopharma?

    AEON Biopharma has 8 total employees.

  • What industry is AEON Biopharma in?

    AEON Biopharma’s primary industry is Drug Discovery.

  • Is AEON Biopharma a private or public company?

    AEON Biopharma is a Public company.

  • What is AEON Biopharma’s stock symbol?

    The ticker symbol for AEON Biopharma is AEON.

  • What is the current stock price of AEON Biopharma?

    As of 13-Nov-2026 the stock price of AEON Biopharma is $0.15.

  • What is the current market cap of AEON Biopharma?

    The current market capitalization of AEON Biopharma is $10.9M.

  • Who are AEON Biopharma’s competitors?

    Ipsen, Vanda Pharmaceuticals, Contineum Therapeutics, Tris Pharma, and Nektar Therapeutics are some of the 7 competitors of AEON Biopharma.

  • What is AEON Biopharma’s annual earnings per share (EPS)?

    AEON Biopharma’s EPS for 12 months was -$4.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process